Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AFT PharmaceuticalsASX:AFP -1.53%76 Price-to-Tangible-Book is 10.60 as of Aug. 10, 2026, which is 19% below its 10-year median of 13.11. GuruFocus rates ASX:AFP with a GF Score™ of 76/100 and a GF Value™ of A$3.37 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 836 Drug Manufacturers companies, AFT Pharmaceuticals ranks worse than 90.91% on this metric.
The historical rank and industry rank for AFT Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:
ASX:AFP'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 7.15 Med: 13.11 Max: 133.78
Current: 10.46
During the past 11 years, AFT Pharmaceuticals's highest Price to Tangible Book Ratio was 133.78. The lowest was 7.15. And the median was 13.11.
ASX:AFP's Price-to-Tangible-Book is ranked worse than 90.91% of 836
companies
in the Drug Manufacturers industry
Industry Median: 2.24
vs ASX:AFP: 10.46
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
AFT Pharmaceuticals Price-to-Tangible-Book Related Terms
AFT Pharmaceuticals Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AFP vs ZTS, UTHR, VTRS: Price-to-Tangible-Book Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
AFT Pharmaceuticals (ASX:AFP) has a Price-to-Tangible-Book of 10.60 as of Aug. 10, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on AFT Pharmaceuticals and its competitors. This is 19% below median its historical median of 13.11. Over the past decade, AFT Pharmaceuticals' Price-to-Tangible-Book has ranged from 7.15 to 133.78. According to the industry distribution chart, AFT Pharmaceuticals ranks #760 out of 836 companies in the Drug Manufacturers industry, placing it in the top 90.9%.
Is AFT Pharmaceuticals' Price-to-Tangible-Book too high?
AFT Pharmaceuticals' current Price-to-Tangible-Book of 10.60 is 19% below median its 10-year median of 13.11. Over the past 10 years, this metric has ranged from a low of 7.15 to a high of 133.78. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.24. AFT Pharmaceuticals' value of 10.60 is 373.2% above this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #760 out of 836 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AFT Pharmaceuticals has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Price-to-Tangible-Book compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #760 out of 836 companies for Price-to-Tangible-Book. This places AFT Pharmaceuticals in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.24. AFT Pharmaceuticals' value of 10.60 is 373.2% above this benchmark. Historically, AFT Pharmaceuticals' own Price-to-Tangible-Book has ranged from 7.15 to 133.78 over the past decade. While the company's 10-year median is 13.11 vs. the industry median of 2.24, AFT Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.24, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current Price-to-Tangible-Book of 10.60 is 373.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current Price-to-Tangible-Book is 10.60, which is 19% below median its own 10-year median of 13.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Modestly Overvalued. The stock's GF Value™ is A$3.37, compared to a current price of A$3.87 — trading 14.8% above its estimated fair value. The current Price-to-Tangible-Book is 10.60, which is 19% below median its 10-year median of 13.11 and 373.2% above the Drug Manufacturers industry median of 2.24. AFT Pharmaceuticals' overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Price-to-Tangible-Book is 10.60 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be overvalued.
The current stock price of A$3.87 is trading 14.8% above its estimated GF Value™ of A$3.37.
GuruFocus considers AFT Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ASX:AFP:
Price-to-Tangible-Book: 10.60 (19% below median its 10-year median of 13.11)
GF Value™: A$3.37 vs. price of A$3.87 (14.8% above fair value)
Industry Position: 373.2% above the Drug Manufacturers median (#760 of 836)
No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
76GF Score
Get the complete analysis for ASX:AFP
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AFP has been successfully added to your 
